Crosstalk Between Colorectal Cancer Cells and Tumour-Associated Macrophages and Tumour-Associated Macrophages
A Randomized, Placebo-Controlled, Phase 2 Study of Tivantinib (ARQ 197) in Combination With Cetuximab and Irinotecan as Second-Line Therapy in Patients.
